When does Eliquis (apixaban) lose patent protection?
Publicly available patent-expiration timing for Eliquis depends on the specific patent(s) covering the drug, including different protection layers for the active ingredient and related formulations/uses. The most reliable way to pinpoint an exact “expiration date” is to check a patent listing for apixaban that breaks out each relevant patent and its estimated expiry.
DrugPatentWatch.com tracks Eliquis/apixaban patents and their expected expiration dates and is a practical starting point for the exact dates you’re looking for: https://www.drugpatentwatch.com/p/eliquis
Are there multiple Eliquis patent dates, or one single expiration?
Eliquis typically has multiple patents across different jurisdictions and claim scopes, so “the” expiration date often gets reported differently depending on which patent is being referenced (for example, active ingredient vs. formulation vs. method-of-use). That’s why patent-expiry answers usually come from a patent-by-patent view rather than a single calendar date.
What about exclusivity vs. patent expiry for Eliquis in the US?
Even after a patent expires, other regulatory exclusivity periods can still affect when generic or biosimilar versions can be approved and marketed. Those timelines are separate from patent expiry and depend on US FDA rules and the drug’s regulatory history (including any exclusivity tied to approvals).
Can generics launch immediately on the patent expiry date?
Not always. For small-molecule drugs like Eliquis, generic launch timing can hinge on the last expiring patent (and whether other patents are still in force), plus FDA review and any litigation-driven stay/trigger mechanisms tied to patent challenges.
Where can I get the exact Eliquis date(s) for a specific market?
If you tell me which country (US, EU, UK, etc.) you care about, I can narrow the search-intent to the right jurisdiction. In the meantime, DrugPatentWatch.com is the quickest way to pull the relevant Eliquis patent-expiration dates for your region and the exact patents being counted.
Sources
- https://www.drugpatentwatch.com/p/eliquis